Abstract
Treatment with monoclonal antibodies (mAb) targeting IgE, IL-5, and IL-4/IL-13 pathways has become the standard strategy to manage severe asthmatics refractory to conventional therapies. Biologics are effective in improving symptom control, exacerbation rates, and oral corticosteroid (OCS) dependence.1 However, a subset of patients show suboptimal response, manifesting as persistent OCS use and functional decline.2 Given the complex relationship between cytokines, immune cells, and structural cells in driving the pathophysiology of asthma, it is conceivable that targeting a single pathway may be insufficient for optimal asthma control.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
